Effect of bovine horn cancer serum on E-rosetting capacity of peripheral blood lymphocytes from normal unaffected animals

Dhingra, Vandana; Gupta, Rajat; Sadana, J. R.

doi:10.1016/s0034-5288(18)32325-7

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Humoral suppressive factors have frequently been recognized: in melanoma patients [29], lymphoma-bearing mice [50], leukemic patients [10], gastric cancer patients [62], feline leukemia virus-bearing cats [15], cows with horn cancer [21], sheep with squamous cell carcinoma [34], patients with ovarian cancer [58], and in BOSCC [38] suppressive factors have been demonstrated. Humoral suppressive factors have frequently been recognized: in melanoma patients [29], lymphoma-bearing mice [50], leukemic patients [10], gastric cancer patients [62], feline leukemia virus-bearing cats [15], cows with horn cancer [21], sheep with squamous cell carcinoma [34], patients with ovarian cancer [58], and in BOSCC [38] suppressive factors have been demonstrated.…”

Section: Discussionmentioning

confidence: 99%

Immune reactivity in cattle with ocular squamous cell carcinoma after intralesional BCG immunotherapy

Klein

Steerenberg

Poelma

et al. 1986

Cancer Immunol Immunother

View full text Add to dashboard Cite

Lymphocyte stimulation with Con A and specific immune reactivity to BCG (antibody formation to BCG and DTH reaction to PPD) were determined in BCG-treated, surgically treated and untreated cows with ocular squamous cell carcinoma. In tumor-bearing cows the Con A-induced proliferation of lymphocytes was reduced when compared to healthy controls. This suppression consisted of a reduced blastogenic response to Con A of lymphocytes from tumor-bearing cows, and the presence of a factor in the sera of these animals, as these sera suppressed the blastogenic response of lymphocytes from healthy cows. BCG had only a minor influence on the suppressive activity. Antibodies to BCG were demonstrated in 50% of the BCG-treated animals. The formation of antibodies was not influenced by intradermal injection of PPD of Mycobacterium bovis. Absorption of a BCG antibody containing serum with BOSCC tumor extracts did not reveal the existence of cross reacting antigens between BCG and BOSCC. Pretherapeutic and posttherapeutic Con A reactivity could not be correlated with clinical response. Of the 30 BCG treated cows 29 developed a positive DTH reaction to PPD. Correlation between clinical response and immune reactivity was seen only with regard to the DTH reaction to PPD: this reaction remained positive for a longer period after treatment in animals with a favorable clinical outcome than in nonresponding animals.

show abstract